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SYSTEMS AND METHODS FOR DIAGNOSIS
AND MONITORING OF
BACTERIA-RELATED CONDITIONS

against microbial antigens and the successful use of antibiotic
therapy in subjects With Crohn’ s disease, as Well as the obser
vation that colitis cannot be induced in animals Without bac
terial ?ora. [5] Additionally, there is evidence for the involve
ment of quorum sensing in the pathogenesis of several

RELATED APPLICATIONS

diseases. For instance, bacteria-producing signaling mol
ecules have been shoWn to be responsible for bio?lm forma

This application claims priority from US. Provisional
Application Ser. No. 60/971 ,228 ?led Sep. 10, 2007, Which is
incorporated herein by this reference.

tion in the lungs. [6] These signaling molecules have been
detected in the sputum of subjects With cystic ?brosis [7] and
have been suspected to be involved in several illnesses of the

GOVERNMENT INTEREST

GI Tract. [5,8,9] Interestingly, signaling molecules have been

Subject matter described herein Was made With US. Gov
ernment support under Grant Number CHE-0416553

shoWn to induce several chemokines and cytokines respon
sible for in?ammation, and inhibit others that are immuno
suppressive in nature, in both in vitro and in vivo experiments.

[10]

aWarded by the National Science Foundation (NSF). The
government has certain rights in the described subject matter.

To date, there is a lack of quick and non- or minimally
invasive methods for the monitoring of acute and chronic

TECHNICAL FIELD

The presently-disclosed subject matter relates to diagnos
ing and monitoring conditions of interest. In particular, the
presently-disclosed subject matter relates to diagnosing and
monitoring bacteria-related conditions.

20

INTRODUCTION AND GENERAL
CONSIDERATIONS

25

bacteria-related conditions. Crohn’s disease, for example,
usually occurs in the loWer part of the small intestine, i.e., the
ileum, but it can affect any part of the digestive tract, from the
mouth to the anus. Crohn’s disease exacerbation is usually
diagnosed With a combination of clinical symptoms and

blood tests for non-speci?c in?ammatory markers, and in
some instances an endoscopy. Methods and systems alloWing

for the non-invasive monitoring of subjects With Crohn’s
disease and other bacteria-related conditions Would alloW for

early identi?cation of exacerbations and, consequently, for
Bacterial quorum sensing (QS) is a cell-to-cell communi

cation phenomenon Whereby bacterial cells produce signal
ing molecules intracellularly, Which are released into the

30

environment. Although these signaling molecules diffuse in
and out of cells, the concentration of the signaling molecules

systems and methods for diagnosing and monitoring bacteria
related conditions.

in the environment re?ects the population of bacteria that are
present in a given environment or, in other Words, the cell

density of the bacterial population. To date, a variety of sig

therapy administration before the onset of a “?are-up,”
thereby decreasing the hardship that such conditions cause to
the subjects. Accordingly, there remains a need in the art for

SUMMARY
35

naling molecules, termed quorum sensing molecules (QSM),
have been identi?ed, including N-acyl homoserine lactones

The presently-disclosed subject matter meets some or all of
the above-identi?ed needs, as Will become evident to those of

(AHLs), Which are used by many gram-negative bacteria; and
oligopeptides, Which are used by many gram-positive bacte
ria. In addition, a family of autoinducers, knoWn as AI-2, has
been identi?ed and is produced by both gram-positive and
gram-negative bacteria. [1] The quorum sensing process
regulates the gene expression necessary for many bacterial

ordinary skill in the art after a study of information provided
in this document. This Summary describes several embodi
ments of the presently-disclosed subject matter, and in many
cases lists variations and permutations of these embodiments.
This Summary is merely exemplary of the numerous and

40

varied embodiments. Mention of one or more representative

activities including bio?lm formation, light production, for
mation of virulence determinants, transfer of carcinogenic Ti
plasmid, and several others. [1] The mechanism by Which

features of a given embodiment is likeWise exemplary. Such
45

feature(s) mentioned; likeWise, those features can be applied
to other embodiments of the presently-disclosed subject mat

bacteria cause disease involves a delay in the expression of
the genes responsible for the formation of virulence factors

until the quorum sensing process produces a large enough
bacterial population that it is capable of overWhelming the
host defense system. [3]

ter, Whether listed in this Summary or not. To avoid excessive

repetition, this Summary does not list or suggest all possible
50

Bacteria are thought to play an important role in many
disorders ranging from infections to chronic in?ammation.
Among those, there are numerous reports in both animal
models and humans that bacteria play a signi?cant role in

embodiments, a method of diagnosing a bacteria-related con
dition in a subject. In some embodiments, the method com

prises providing a biological sample from a subject; deter
55

mining an amount in the sample of at least one quorum

sensing molecule (QSM); and comparing the amount of the at
least one QSM in the sample, if present, to a control level of
the at least one QSM. If there is a measurable difference in the
amount of the at least one QSM in the sample as compared to
60

the control level, the subject can then be diagnosed as having
the bacteria-related condition of interest or a risk thereof.

gastrointestinal (GI) diseases, such as in?ammatory boWel
disease (IBD). [4] In?ammatory boWel disease, Which
includes Crohn’s disease (CD) and ulcerative colitis (UC), is
a chronic gastrointestinal in?ammatory condition With
unknown etiology. To support the involvement of bacteria in
these diseases are the identi?cation of serologic markers

combinations of such features.

The presently-disclosed subject matter provides, in some

Further, it is appreciated that once the concentration of the
signaling molecules reaches a speci?c level, the bacteria can

monitor population density and alter their group behavior. [3]
In this regard, the QSMs bind to their sensor/regulatory pro
tein, resulting in the activation of quorum sensing-dependent
virulence/target genes.

an embodiment can typically exist With or Without the

In some embodiments, the QSM is an N-acyl homoserine
lactone (AHL) or an autoinducer-2 (AI-2). In some embodi

ments, the AHL is selected from: N-butyryl homoserine lac
65

tone (C4-HSL), N-hexanoyl homoserine lactone (C6-HSL),

N-(3 -oxo)-hexanoyl homoserine lactone (3 -oxo-C6-HSL),
N-octanoyl homoserine lactone (C8-HSL), N-(3 -oxo)-oc

US 8,663,927 B2
3

4

tanoyl homoserine lactone (3-oxo-C8-HSL), N-decanoyl

embodiments, the kit comprises a cell sensing system in
accordance With the presently-disclosed subject matter and
instructions for using the kit.
Accordingly, it is an object of the presently-disclosed sub
ject matter to provide systems, methods, and kits for diagnos
ing and monitoring a bacteria-related condition of interest in
a subject. This object is achieved in Whole or in part by the

homoserine lactone (ClO-HSL), N-dodecanoyl homoserine
lactone (Cl2-HSL), N-(3-oxo)-dodecanoyl homoserine lac
tone (3-oxo -C l 2-HSL), N-tetradecanoyl homoserine lactone
(Cl4-HSL), and combinations thereof.
In some embodiments, determining the amount in the

sample of the at least one QSM comprises determining the
amount in the sample of the at least one QSM using a cell

presently-disclosed subject matter.
An object of the presently-disclosed subject matter having

sensing system. In some embodiments, the cell sensing sys
tem comprises a bacterial cell; a regulatory protein Within the

been stated hereinabove, and Which is achieved in Whole or in

bacterial cell for binding at least one QSM; and, a reporter

part by the presently-disclosed subject matter, other objects

molecule Within the bacterial cell for detecting binding of the
QSM to the regulatory protein, Where the reporter molecule
generates a detectable signal upon binding of the QSM to the
regulatory protein. In some embodiments, the cell sensing
system further comprises a substrate supporting the bacterial
cell and a signal reader for detecting the signal generated by
the reporter molecule. In some embodiments, the bacterial
cell comprises a heterologous reporter gene cassette that
comprises a promoter operatively linked to a nucleotide
sequence encoding the reporter molecule. In some embodi
ments, the reporter gene cassette is luxCDABE. In some

embodiments, the reporter gene cassette is luxCDABE, the
promoter is PM”, and the regulatory peptide is RhlR. In some
embodiments, the reporter gene cassette is luxCDABE, and
the promoter and regulatory peptide are PMS, and LasR,

and advantages Will become evident to those of ordinary skill
in the art after a study of the folloWing description of the

presently-disclosed subject matter, Figures, and non-limiting

Examples.
BRIEF DESCRIPTION OF THE DRAWINGS
20

FIG. 2 contains a schematic representation ofAHL-depen
25

respectively.
Further, in some embodiments of the presently-disclosed

subject matter, the QSM-regulatory complex has binding
a?inity for the promoter such that the regulatory peptide
binds the promoter and activates expression of the reporter

30

cassette luxCDABE.
FIG. 3 includes calibration curves for exemplary cell sens

1075 (right panel), Where bacterial cells Were incubated With

different N-acyl-DL-homoserine lactones, namely, N-hex
35

anoyl-DL-homoserine lactone (upWard-pointing triangle),
N-butyryl-DL-homoserine lactone (square), N-octanoyl-DL
homoserine lactone (circle), N-dodecanoyl-DL-homoserine
lactone (diamond), and N-tetradecanoyl-DL-homoserine lac
tone (doWnWard-pointing triangle), and Where the signals

ently-disclosed methods, the determined amount of the at
least one QSM can be used to select or modify a treatment for
the bacteria-related condition of interest. In some embodi
ments, a method for determining Whether to initiate or con
tinue prophylaxis or treatment of a bacteria-related condition

dent regulation of quorum sensing in LuxR/LuxI-type sys
tems (FIG. 2A) and a schematic representation of the plas
mids pSBl075 and pSB406, Which contain lasR and rhlR
regulatory genes, respectively, fused With the reporter gene

ing systems employing plasmid pSB406 (left panel) and pSB

molecule to thereby generate a detectable signal. In some
embodiments, the detectable signal is bioluminescence. In
some embodiments, an amount of the detectable signal cor
relates to a concentration of the QSM.
Still further provided, in some embodiments of the pres

FIG. 1 includes the chemical structures of N-acyl

homoserine lactones (AHLs) produced by different bacterial
species, and the respective LuxI homologues responsible for
AHL synthesis in each bacterial species.

have been corrected With respect to a blank, and Where data
40

shoWn are the averageione standard deviation.

FIG. 4 includes an evaluation of saliva matrix effects using

an exemplary biosensing system employing plasmid pSB406

of interest in a subject is provided. In some embodiments, the

method comprises providing a series of biological samples

and N-hexanoyl-DL-homo serine lactone as an analyte, Where

over a time period from the subject; analyZing the series of
biological samples to determine an amount in each of the

the dose-response curve is achieved by analyte standard addi
tion to a pool of saliva samples from four healthy subjects
(upWard-pointing triangles) and the reference calibration
curve (square) is obtained during the same analytical run, and
Where the signals have been corrected With respect to the
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biological samples of the at least one QSM; and, comparing
any measurable change in the amounts of the at least one

QSM in each of the biological samples to thereby determine
Whether to initiate or continue the prophylaxis or treatment of

the bacteria-related condition of interest.
In some embodiments of the methods of the presently
disclosed subject matter, the subject is human. In some

50

FIG. 5 is a graph depicting levels of short and long chain
AHLs and fecal lactoferrin detected in boWel secretion

samples from in?ammatory boWel disease (IBD) subjects.

embodiments, a biological sample is provided from the sub
ject. In some embodiments, the biological sample is a saliva

sample, and, in some embodiments, the biological sample, is

55

a stool sample.
In some embodiments, the bacteria-related condition is a
bacterial infection. In some embodiments, the bacteria-re
lated condition is an in?ammation, such as, in some embodi
ments, a chronic in?ammation. In some embodiments, the
bacteria-related condition of interest is a condition of the
gastro-intestinal tract. In some embodiments, the condition is

an in?ammatory boWel disease (IBD), including, in some
embodiments, Crohn’s disease and ulcerative colitis.
Still further provided, in some embodiments of the pres
ently-disclosed subject matter, is a kit for diagnosing a bac
teria-related condition of interest in a subject. In some

blank, and Where data shoWn are the averageione standard
deviation.

FIG. 6 is a graph shoWing a comparison betWeen long chain
AHL levels in diseased and control subjects.
FIG. 7 contains graphs depicting levels of short and long
chainAHLs detected in saliva samples from IBD subjects and

control subjects.
FIG. 8 is a graph depicting levels of short and long chain
60

AHLs detected in stool samples from infants admitted to a

Neonatal Intensive Care Unit (NICU).
FIG. 9 includes a diagram of a microcentrifuge compact

disc (CD) micro?uidics platform (FIG. 9A) and a diagram of
a micro?uidics structure (FIG. 9B) of the CD micro?uidics
65

platform containing small Wells for the addition of sensing
bacterial cells and samples, and a detection chamber linked to

the Wells by a mixing channel.
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FIG. 10 is a schematic representation of an exemplary CD
micro?uidics platform attached to a rotor, Where biolumines

population. Once the concentration of the signaling mol

cent reactions in the micro?uidic structures are detected by a

population density and alter their group behavior, including,
but not limited to, altering and controlling the expression of

ecules reaches a speci?c level, the bacteria can monitor their

photomultiplier tube (PMT) attached to a transducer that
generates a readable signal.
FIG. 11 is a graph depicting results of a time-course study

certain specialiZed genes depending on the siZe of the bacte
rial population. This phenomenon is termed “quorum sens
ing” and is a process Whereby the expression of genes neces

using N-hexanoyl-DL-homoserine lactone in an exemplary
CD micro?uidics platform.

sary for many bacterial activities, such as bio?lm formation,

FIG. 12 is a graph depicting the reproducibility of an exem

light production, formation of virulence factors, and others, is
regulated. For example, the mechanism by Which bacteria

plary CD micro?uidics platform for detecting quorum sens

ing molecules (QSMs).

cause disease involves a delay in the expression of genes
responsible for formation of virulence factors until the quo
rum sensing process produces a su?iciently large bacterial
population that is capable of overWhelming a host’s defense

FIG. 13 is a graph depicting the ability of an exemplary CD
micro?uidics platform to detect QSMs in a biological sample.
FIG. 14 is a calibration curve obtained using various con

centrations of autoinducer-2 (AI-2).

system.
The signaling molecules that are involved in the process of
quorum sensing are referred to herein as “quorum sensing

DESCRIPTION OF EXEMPLARY
EMBODIMENTS

molecules” (QSM). Many gram-negative bacteria use N-acyl
The details of one or more embodiments of the presently
disclosed subject matter are set forth in this document. Modi

20

tive bacteria employ oligopeptides. Additionally, a family of

?cations to embodiments described in this document, and
other embodiments, Will be evident to those of ordinary skill
in the art after a study of the information provided in this

document. The information provided in this document, and
particularly the speci?c details of the described exemplary
embodiments, is provided primarily for cleamess of under

autoinducers, knoWn as autoinducer-2 (AI-2), can function as

QSMs and are produced by both gram-positive and gram

negative bacteria.
25

ditions, information about the timing and level of expression

standing and no unnecessary limitations are to be understood

of QSMs in bacteria-related conditions is desirable to obtain.
30

Systems and methods capable of identifying the presence of
and quantitating QSMs in a particular bacteria-related condi
tion of interest can provide information useful for under
standing hoW each bacteria-related condition evolves and is
maintained. Such understanding can prove useful in the diag

35

nosis and characterization of a number of bacteria-related
conditions and can alloW these conditions to be diagnosed

While the folloWing terms are believed to be Well under

stood by one of ordinary skill in the art, the following de?ni
tions are set forth to facilitate explanation of the presently

disclosed subject matter.
Unless de?ned otherWise, all technical and scienti?c terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to Which the presently

and/or monitored such that a treatment can be selected or

disclosed subject matter belongs. Although any methods,
devices, and materials similar or equivalent to those described
herein can be used in the practice or testing of the presently

Given the role of the OS process and QSMs in bacterial
cell-to-cell communication, as Well as the role of this phe
nomenon in the pathogenesis of many bacteria-related con

therefrom. In case of con?ict, the speci?cation of this docu

ment, including de?nitions, Will control.

homoserine lactones as their QSMs, While many gram-posi

modi?ed depending on the amount of QSMs in a biological
40

disclosed subject matter, representative methods, devices,

sample from a subject.
The presently-disclosed subject matter includes systems,
methods, and kits for diagnosing and/or monitoring a bacte
ria-related condition of interest in a subject. The term “bac
teria-related condition” is used herein to refer to conditions

and materials are noW described.

FolloWing long-standing patent laW convention, the terms
ence to “a cell” includes a plurality of such cells, and so forth.

Whose symptoms are caused directly or indirectly by the
invasion and/ or coloniZation of bacteria. For example, in
some embodiments of the presently-disclosed subject matter,

Unless otherWise indicated, all numbers expressing quan
tities of ingredients, properties such as reaction conditions,

the bacteria-related condition can be a bacterial infection, an
acute or chronic in?ammation, a condition of the gastro

“a”, “an”, and “the” refer to “one or more” When used in this

application, including the claims. Thus, for example, refer

45

and so forth used in the speci?cation and claims are to be

understood as being modi?ed in all instances by the term
“about.” Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this speci?cation and claims
are approximations that can vary depending upon the desired

50

properties sought to be obtained by the presently-disclosed
subject matter.

method includes: providing a biological sample from the
55

As used herein, the term “about,” When referring to a value
or to an amount of mass, Weight, time, volume, concentration
or percentage is meant to encompass variations of in some

embodiments 120%, in some embodiments 110%, in some
embodiments 15%, in some embodiments 11%, in some
embodiments 10.5%, and in some embodiments 10.1% from
the speci?ed amount, as such variations are appropriate to

perform the disclosed method.
Bacteria communicate With neighboring bacterial cells by
producing signaling molecules intracellularly that are
released into the environment, and the concentration of these
signaling molecules re?ects the cell density of the bacterial

intestinal tract, or an in?ammatory boWel disease (IBD), such
as Crohn’s disease (CD) or ulcerative colitis (UC).
In some embodiments, a method of detecting and/or moni
toring a bacteria-related condition is provided, Which can lead
to diagnosis of the condition. In some embodiments, the
subject; determining an amount in the sample of at least one
QSM; comparing the amount of the at least one QSM in the
sample, if present, to a control level of the at least one QSM,
Wherein the subject is diagnosed as having the bacteria-re
lated condition of interest or a risk thereof if there is a mea

60

surable difference in the amount of the at least one QSM in the
sample as compared to the control level.
The term “biological sample” as used herein refers to a

sample capable of comprising a QSM, Which is derived from
65

a subject. The biological sample can be utiliZed for the detec
tion of the presence and/or level of a QSM of interest in the

sample. Exemplary biological ?uids include, but are not lim
ited to, saliva, stool, sputum, blood, plasma, serum, and urine.

US 8,663,927 B2
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The presently-disclosed subject matter further provides, in

In some embodiments, the biological sample comprises
saliva. In some embodiments, the sample comprises stool.

some embodiments, a method for determining Whether to

In some embodiments, the QSM is selected from the

initiate or continue prophylaxis or treatment of a bacteria

groups consisting of: N-acyl homoserine lactone (AHL) and
autoinducer-2 (AI-2). It is appreciated that the family of

related condition of interest in a subject. In some embodi

ments, the method comprises providing a series of biological
samples over a time period from the subject; analyZing the

QSMs knoWn as AI-2 includes a number of QSMs that inter

series of biological samples to determine an amount of at least

convert into each other and are capable of existing in equilib
rium in solution. [22] Further, many different types of AHLs
have been reported in the literature. In some embodiments of
the presently-disclosed subject matter, the AHL is selected

one QSM in each of the biological samples; and comparing
any measurable change in the amounts of the at least one

QSM in each of the biological samples. Any changes in the
amounts of the at least one QSM over the time period can be

from: N-butyryl homoserine lactone (C4-HSL), N-hexanoyl
homoserine lactone (C6-HSL), N-(3-oxo)-hexanoyl
homoserine lactone
(3-oxo-C6-HSL), N-octanoyl
homoserine lactone (C8-HSL), N-(3-oxo)-octanoyl
homoserine lactone (3-oxo-C8-HSL), N-decanoyl
homoserine lactone (ClO-HSL), N-dodecanoyl homoserine
lactone (Cl2-HSL), N-(3-oxo)-dodecanoyl homoserine lac
tone (3-oxo -C l 2-HSL), N-tetradecanoyl homoserine lactone
(Cl4-HSL), and combinations thereof.

used to predict clinical outcome, determine Whether to initiate
or continue the prophylaxis or therapy of the bacteria-related
condition, and Whether a current therapy is effectively treat
ing the bacteria-related condition. For example, a ?rst time
point can be selected prior to initiation of a treatment and a
second time point can be selected at some time after initiation
of the treatment. QSM levels can be measured in each of the

samples taken from different time points and qualitative and/
20

The terms “diagnosing” and “diagnosis” as used herein
refer to methods by Which the skilled artisan can estimate and

or quantitative differences noted. A change in the amounts of
the QSM levels from the ?rst and second samples can be

even determine Whether or not a subject is suffering from a

correlated With prognosis, determining treatment ef?cacy,
and/or progression of the disease in the subject.

given bacteria-related condition. The skilled artisan often

The terms “correlated” and “correlating,” as used herein in

makes a diagnosis on the basis of one or more diagnostic 25 reference to the use of diagnostic and/ or prognostic biomar

indicators. The presently-disclosed subject matter provides

kers, such as QSMs, refers to comparing the presence or
quantity of the QSM in a subject to its presence or quantity in
subjects knoWn to suffer from, or knoWn to be at risk of, a

for the measurement of one or more QSMs as diagnostic

indicators, the amount (including presence or absence) of
Which is indicative of the presence, severity, or absence of a
bacteria-related condition.

Along With diagnosis, clinical prognosis is also an area of
great concern and interest. It is important to knoW the aggres
siveness of particular bacteria-related conditions and the like
lihood of remissions and/or exacerbations in order to plan the
most effective therapy. Crohn’s disease, for example, is man
aged by several alternative strategies. In some cases, antibi

given condition (e.g., Crohn’s disease); or in subjects knoWn
30
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to be free of a given condition, i.e. “normal subjects” or
“control subjects”. For example, a level of a QSM in a bio

logical sample can be compared to a QSM level determined to
be associated With a speci?c type of bacteria-related condi
tion. The sample’s QSM level is said to have been correlated
With a diagnosis; that is, the skilled artisan can use the QSM
level to determine Whether the subject suffers from a speci?c

otic therapy may be successfully utiliZed, While, in other

type of bacteria-related condition, and respond accordingly.

cases, anti-in?ammatory, steroid, or antibody therapies, or

Alternatively, the sample’s QSM level can be compared to a
control QSM level knoWn to be associated With a good out
come (e. g., the absence of a bacteria-related condition), such

combinations thereof, are employed. If a more accurate prog

no sis can be made, appropriate therapy, and in some instances
less severe therapy for the subject can be chosen. Measure

40

as an average level found in a population of normal subjects.

ment of one or more QSMs can be useful in order to separate

subjects With good prognosis, Who Will need no further
therapy, from those more likely to have recurring symptoms
or exacerbations, Who might bene?t from more intensive

45

treatments.

compared to the threshold level.
As noted, in some embodiments, multiple determinations

As such, “making a diagnosis” or “diagnosing”, as used
herein, is further inclusive of making a prognosis, Which can
provide for predicting a clinical outcome (With or Without

medical treatment), selecting an appropriate treatment (or

In certain embodiments, a diagnostic or prognostic biom
arker is correlated to a condition or disease by merely its
presence or absence. In other embodiments, a threshold level
of a diagnostic or prognostic biomarker can be established,
and the level of the indicator in a subject sample can simply be

of one or more diagnostic or prognostic biomarkers can be

Whether treatment Would be effective), or monitoring a cur

made, and a temporal change in the marker can be used to
determine a diagnosis or prognosis. For example, a diagnostic

rent treatment and potentially changing the treatment, based

marker can be determined at an initial time, and again at a

on the measure of QSMs present in a sample. As such, in some
embodiments, a method of diagnosing a bacteria-related con

second time. In such embodiments, an increase in the marker
from the initial time to the second time can be diagnostic of a
particular type or severity of bacteria-related condition, or a

dition is provided that further comprises selecting or modi
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given prognosis. LikeWise, a decrease in the marker from the

fying a treatment for the bacteria-related condition that is
based on the determined amount of the at least one QSM.
Further, in some embodiments of the presently-disclosed sub

ject matter, multiple determinations of the amounts of QSMs
over time can be made to facilitate diagnosis and/or progno
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sis. A temporal change in the amount of QSMs can be used to
predict a clinical outcome, monitor the progression of the

The phrase “determining an amount,” and grammatical

bacteria-related condition and/or e?icacy of appropriate
therapies directed against the bacteria-related condition of
interest. In such an embodiment, for example, one might

initial time to the second time can be indicative of a particular
type or severity of bacteria-related condition, or a given prog
nosis. Furthermore, the degree of change of one or more
markers can be related to the severity of the bacteria-related
condition and future adverse events.

variations thereof, When used herein in reference to a QSM,
refers to a qualitative (e. g., present or not present in the
65

measured sample), quantitative (e.g., hoW much is present),

expect to see a decrease in the amount of QSMs in a biological

or both, measurement of a QSM. The “control level” is an

sample over time during the course of effective therapy.

amount (including the qualitative presence or absence) or

